Douglas Flora: August issue of AI in Precision Oncology and our first Special Issue: Cancer Screening
Douglas Flora shared a post on LinkedIn:
“I’m thrilled to announce the arrival of our August issue of AI in Precision Oncology and our first Special Issue: Cancer Screening.
A huge congratulations to the guest editor, City of Hope’s Toufic Kachaamy MD FASGE AGAF FACG, for pulling together this transformative issue.
Exciting advancements are happening in oncology as we harness the power of AI, large datasets, and polygenic risk scores to better identify and characterize cancer risk.
Better screening, early identification, and detection are key to changing outcomes and saving lives—and these tools are already making an impact in cancer screening.
In this special issue, we explore the convergence of precision medicine, AI, and advanced cancer screening techniques, which marks a monumental leap forward in oncology.
As Dr. Kachaamy writes in his editorial, “Data-driven personalized cancer screening is on the cusp of revolutionizing early detection, improving treatment outcomes, and reducing unnecessary interventions.”
This journey towards personalized oncology promises better outcomes and a brighter future for patients worldwide.
I highly recommend checking out this issue for those interested in diving deeper. It’s packed with valuable insights that highlight the future of cancer care. More to follow, as a few more articles will be released ahead of print this week and next.
Link to Dr. Kachaamy’s editorial.
The Convergence of Precision Medicine, Artificial Intelligence, and Cancer Screening: A Journey Towards Data-Driven Personalized Oncology Early Interventions .
As always, DM me if YOU have an idea for an editorial, a manuscript you want to be published expeditiously to our audience or other ideas for this young journal.
We are building it for you, and participation is welcome.”
Source: Douglas Flora/LinkedIn
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.